Inventia Life Science Accelerates Growth With $25M Series B And Launches 3D Cell Culture Platform Into Us Market
Dec 15, 2021•over 3 years ago
Amount Raised
$25 Million
Round Type
series b
Description
Inventia Life Science, a world leader in advanced 3D cell cultures for research and clinical purposes, has today announced the close of a US $25M Series B funding round, led by Blackbird Ventures. Inventia has also announced the launch of its US operations with the appointment of Dwayne Dexter as its Director of US Sales. Through this Series B round of financing, Inventia plans to market its RASTRUMTM 3D cell culture platform worldwide and grow its team from 36 to 150 employees by the end of 2024. In particular, it aims to develop a strong presence in the US, where the biomedical research and drug discovery markets are currently estimated to be worth more than US $40 billion
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech